Saredutant succinate (SR48968C)
Sponsors
Sanofi
Conditions
Depressive Disorder
Phase 3
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
CompletedNCT00250601
Start: 2005-04-30End: 2007-07-31Updated: 2012-02-17
A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression
CompletedNCT00250653
Start: 2005-05-31End: 2007-04-30Updated: 2012-02-17
An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
CompletedNCT00250627
Start: 2004-12-31End: 2006-12-31Updated: 2008-12-23
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
CompletedNCT00250614
Start: 2005-04-30End: 2006-10-31Updated: 2010-06-09
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
CompletedNCT00256113
Start: 2004-12-31End: 2006-12-31Updated: 2018-04-20